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Abstract 
Aims/hypothesis: The patient self-administered Michigan Neuropathy Screening Instrument 
(MNSI) is used to diagnose diabetic peripheral neuropathy. We examined whether MNSI might 
also provide information on risk of death and cardiovascular (CV) outcomes.  
Methods: We divided 8463 patients with type 2 diabetes, chronic kidney disease (CKD) and/or 
CV disease from ALTITUDE into independent training (n=3252) and validation (n=5211) sets. 
In the training set we identified specific questions independently associated with a CV composite 
outcome [CV death, resuscitated cardiac arrest, non-fatal myocardial infarction/stroke, heart 
failure hospitalization (HF)]. We then evaluated the performance of these questions in the 
validation set.  
Results: In the training set, three questions (Are your legs numb? Have you ever had an open 
sore on your foot? Do your legs hurt when you walk?) were significantly associated with the CV 
composite outcome. In the validation set, after multivariable adjustment for key covariates, one 
or more positive responses (n=3079, 59.1%) was associated with higher risk of CV composite 
outcome (HR 1.54, 95% CI 1.28-1.85, p<0.001), HF (HR 1.73, 95%CI 1.28-2.33, p<0.001), 
myocardial infarction (HR 1.86, 95%CI 1.25-2.76, p=0.002) and stroke (HR 1.74, 95%CI 1.19-
2.53, p= 0.004) relative to those who answered “no” to all questions. Associations were stronger 
if patients answered positively to all three questions (n=552, 11%). The addition of the total 
number of affirmative responses to existing models significantly improved Harrell’s C statistic 
for CV composite outcome (0.70 vs 0.71, p= 0.010), continuous net reclassification improvement 
(+22%, (+10%, +31%), p=0.027) and integrated discrimination improvement (+0.9%, (+0.4%, 
+2%), p=0.007). 
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Conclusions/interpretation: We identified three questions from MNSI that add additional 
prognostic information in patients with type 2 diabetes, CKD and/or CV disease. If externally 
validated, these questions may be integrated into the clinical history to augment prediction of CV 
events in high-risk type 2 diabetes patients.   
Keywords: Type 2 diabetes, chronic kidney disease, cardiovascular disease, Michigan 
Neuropathy Screening Instrument, death, cardiovascular outcomes. 
Abbreviations  
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Introduction 
Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 
diabetes. It is one of the major causes of foot ulcers and subsequent amputations, and is also 
associated with a higher risk of all-cause and cardiovascular (CV) mortality than in patients 
without DPN (1-3). Poor glycemic control is the strongest risk factor for the development of 
DPN, while age and duration of DM, as well as other co-morbidities (dyslipidemia, 
hypertension, diabetic retinopathy, nephropathy, smoking), are also associated with DPN (4,5). 
Previous studies have shown that DPN is present in 30-50% of patients with DM (6,7). 
Therefore, screening and timely diagnosis of DPN is important for improving foot care and 
highlighting the risk of adverse CV outcomes.  
While electromyography, electroneurography and sural nerve biopsy are the gold standard for 
diagnosing DPN, the Michigan Neuropathy Screening Instrument (MNSI), introduced in 1994, is 
considered to be an alternative diagnostic tool. The MNSI includes two separate assessments, a 
15-item self-administered questionnaire about symptoms and a lower extremity examination that 
includes inspection and assessment of vibratory sensation and ankle reflexes (8). The MNSI was 
developed to diagnose DPN in clinical practice and is also used in large clinical trials (9-11). 
However, its’ value in risk stratification has not been ascertained. Therefore, we investigated 
whether the MNSI questionnaire offers additional information about risk of death and major CV 
events in high-risk patients with type 2 diabetes, and chronic kidney disease (CKD) and/or CV 
disease. 
 
Methods  
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Participants The Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints 
(ALTITUDE, NCT00549757) was a double-blind, randomized, controlled trial conducted among 
8561 patients with type 2 diabetes and CKD and/or CV disease who were randomly assigned to 
receive 300 mg of aliskiren per day or placebo, added to an angiotensin-converting-enzyme 
inhibitor or angiotensin II receptor blocker. Patients were followed up for a median of 2.6 years 
(IQR 2.0-3.2). The trial design and results are published (12,13). 
Out of the 8561 randomized patients, 8463 completed the self-administered MNSI questionnaire 
(Supplementary material 1) at baseline and were included in this post-hoc analysis (the 
remaining 98 patients did not complete the questionnaire). Based on the time of randomization, 
we divided this cohort into an independent training (n=3252, randomized 2007-2008) and 
validation set (n=5211, randomized 2009-2011).  
Study design In the training set, we identified specific questions that were independently 
associated with the CV composite outcome [CV death, resuscitated cardiac arrest, non-fatal 
myocardial infarction/stroke, heart failure hospitalization (HF)]. These questions were then 
evaluated in the validation set in unadjusted and adjusted models to confirm their potential 
independent association with clinical outcomes.  
Statistical analysis 
Baseline characteristics were stratified by patient group (training/validation set). Continuous data 
are presented as the mean ± standard deviation except for triglycerides and urinary albumin-to-
creatinine ratio, which are presented as median [25–75th percentile]. Categorical variables are 
expressed as proportions and were compared by the chi-square test, while continuous variables 
were compared using t-tests or Wilcoxon rank-sum tests, as appropriate. Using patients in the 
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training data set, forward stepwise-selection techniques were used with threshold p-value = 0.05 
to identify specific questions that were independently associated with the CV composite outcome 
without adjustment for any other variables. We further tested the null hypothesis that all selected 
questions were equally associated (i.e. equal hazard ratios (HR)) with the outcome of interest 
versus the alternative that one or more of the selected questions were differentially related to the 
outcome (i.e. one or more HRs different from the others). These selected questions were then 
tested as predictors in adjusted Cox proportional hazards models using the validation data set. 
We used these questions in two models. First we estimated the risk associated with an 
affirmative answer to any of the three questions compared to those with no affirmative answers. 
Next, we estimated the risk associated with each specific number of affirmative answers 
compared to a reference of zero affirmative answers. Proportional hazards regression models 
were used to assess the association between the questions and CV outcomes. Model 1 was 
adjusted for the randomized study treatment. Model 2 was adjusted for baseline covariates: age, 
sex, race, smoking status, systolic blood pressure, eGFR, urinary albumin to creatinine ratio, 
history of heart failure, myocardial infarction, stroke, atrial fibrillation, diabetic nephropathy, 
diabetic retinopathy, amputation, claudication, unstable angina, coronary revascularization, 
duration of diabetes, HbA1c, and randomized treatment (14). Harrell’s C statistics (compared 
using a transformation of the equivalent Somers' D parameters (15)), continuous net 
reclassification improvement (NRI) and integrated discrimination improvement (IDI) were 
obtained by comparing the described multivariable Cox models with and without the inclusion of 
the variable identifying the number of “yes” responses from among the chosen MNSI questions 
and was assessed at 3 years post-randomization. Assessment of the proportional hazards 
assumption was performed using Schoenfeld residuals. Two-sided P-values <0.05 were 
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considered statistically significant. Analyses were performed using Stata version 13.1 (Stata 
Corp., College Station, TX, USA). 
 
Results 
The 8463 participants were divided into a derivation (n=3252) and a validation group (n=5211). 
Baseline characteristics in these two groups are presented in Table 1. Patients included in the 
training and validation groups were qualitatively similar. All pair-wise correlations between 
MNSI questions were less than +0.40. In the training data set, we identified three questions 
which were independent predictors of the CV composite outcome: question 1- Are your legs 
and/or feet numb? (HR 1.25 95% CI 1.04-1.50, p=0.019), question 8-Have you ever had an open 
sore on your foot? (HR 1.45, 95% CI 1.18-1.76, p<0.001) and question 12- Do your legs hurt 
when you walk? (HR 1.63, 95% CI 1.36-1.95, p<0.001). The associations of three questions with 
specific CV outcomes in the training data set are shown in Supplementary Table 1. After 
adjusting for other baseline covariates, we found no evidence that the HRs associated with any of 
the three questions were significantly different from the others with respect to any of the 
outcomes. 
In the validation set, 3079 patients (59.1%) answered “yes” to at least one of these three 
questions. Of these, 29.7% answered positively to one, 18.8% to two and 10.6% to three 
questions.  
We then analyzed the associations between different combinations of individual questions and 
CV outcomes in the validation dataset (Table 3, Graph 1). In unadjusted models, patients who 
answered “yes” to at least one of the three questions demonstrated a higher risk of the CV 
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composite outcome (HR 1.77, 95% CI 1.48-2.11, p<0.001), all-cause death (HR 1.48, 95% CI 
1.19-1.84, p<0.001), CV death (HR 1.51, 95% CI 1.14-2.01, p=0.004), heart failure 
hospitalization  (HR 2.00, 95%CI 1.50-2.68, p<0.001), myocardial infarction (HR 2.20, 95%CI 
1.51-3.21, p<0.001) and stroke (HR 1.95, 95%CI 1.36-2.78, p<0.001), relative to those who 
answered “no” to all of the questions. After multivariable adjustment, the excess risk associated 
with a positive answer to a question was reduced by a quarter to a half, but remained clinically 
important and retained statistical significance (with the exceptions of all-cause death and CV 
death). These associations became even stronger if patients answered positively to multiple 
questions in relation to all CV outcomes, except stroke (Supplementary Table 2). The addition of 
the total number of affirmative responses to existing models significantly improved Harrell’s C 
statistic for CV composite outcome (0.70 vs 0.71, p= 0.010), continuous net reclassification 
improvement (+22%, (+10%, +31%), p=0.027) and integrated discrimination improvement 
(+0.9%, (+0.4%, +2.1%), p=0.007). For all other outcomes, C-statistic was improved by +0.00 to 
+0.02, NRI by +17% to +25% and IDI by +0.3% to ++0.8% (details in Table 4).   
Discussion 
This study identified three out of 15 simple questions from the MNSI which provided additional 
prognostic information about the risk of all-cause death, CV death and a composite CV outcome, 
as well as its components, in patients with type 2 diabetes and CKD and/or CV disease. While 
the MNSI questionnaire has previously been used to screen for DPN (9-11), this is the first time 
these questions have been used as predictors of risk of CV events. A positive answer to any one 
of the three identified questions was associated with a higher risk of adverse CV events, and the 
relationship was even stronger if the answer to multiple questions were positive. Furthermore, 
when patients’ characteristics and other CV risk factors were considered, a positive answer to 
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each of these three questions provided additional prognostic information concerning the risk of 
the outcomes described.  
The DCCT/EDIC study investigators examined the performance of each item in the MNSI 
questionnaire and examination in confirming the diagnosis of DPN. These investigators 
concluded that a reduced index of four questions performed nearly as well as the more extensive 
instrument (11). Two of these four questions (question 1- Are your legs and/or feet numb? and 
question 8-Have you ever had an open sore on your foot?) were also identified by us as 
important predictors of CV outcomes. 
As CV risk factors and microvascular disease are associated with both DPN and CVD in people 
with type 2 diabetes, it is perhaps unsurprising that instruments designed to detect DPN might 
also predict future CVD.  That the risks associated with simple, questions are strong, and only 
marginally attenuated by multivariable adjustment that accounts for variables associated with the 
risk of experiencing the primary outcome of the study is more striking.  Etiologic explanations 
for this are unclear.  Alternatively, or additionally, these questions may capture unmeasured 
pathways (for example chronic inflammation in association with a history of an open sore), or 
more global aspects of vascular damage in association with type 2 diabetes. A similar hypothesis 
has been invoked to account for the repeated observation that abnormalities of retinal vascular 
architecture, which are thought to mimic patterns in the cerebrovascular territory, predict 
outcomes independent of other vascular risk factors (16,17). 
It is well known that CV events are a leading cause of morbidity and mortality in patients with 
type 2 diabetes. Therefore, in clinical settings, there is a growing need for tools which could help 
accurately assess the risk of adverse events in type 2 diabetes patients. While study of residual 
confounding and alternative pathways are of interest in understanding mechanisms to identify 
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new therapeutic targets, current clinical practice should be more concerned with identification of 
high risk individuals to whom existing therapies can be targeted.  In clinical practice, 
complication assessment will also suffer from similar levels of imprecision as in ALTITUDE 
and other studies, and performance of additional tests, such as markers of inflammation are time 
consuming and expensive.  Inclusion of just three simple, yet strongly predictive, questions may 
therefore be of substantial importance to clinical practice. Prediction models are widely used in 
medicine as potential aids in clinical understanding and therapeutic decision-making, as well as 
better assessment of prognosis. However, before a new risk prediction model could be adapted in 
clinical practice and widely used, it needs to be externally validated, to assess its generalizability 
(18-20). In this analysis, we demonstrated internal validation by showing that three questions 
identified from the derivation set provided statistically significant prognostic information in an 
independent validation set.   
There are several limitations of this study that need to be noted. First of all, all patients were 
included in ALTITUDE based on same inclusion criteria, and although divided into statistically 
independent derivation and validation groups, the two groups were overall similar. Therefore, the 
lack of external validation, as well as the fact that these findings may not be generalizable to 
other population of patients with type 2 diabetes is considered an important limitation. In 
addition, we are limited by the fact that the cohort included in this clinical trial were high-risk 
type 2 diabetes patients, who were therefore more susceptible to adverse CV outcomes.  
In conclusion, we believe that these three questions represent a simple, non-invasive and 
inexpensive tool which could potentially provide additional prediction information in clinical 
practice. If externally validated in type 2 diabetes patients with lower CV risk, these questions 
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may be integrated into the clinical history to augment the prediction of CV events in high-risk 
type 2 diabetes patients.  
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Table 1. Baseline characteristics by patient group 
 
Characteristic Derivation 
N=3252 
Validation 
N=5211 
Age, years  65.2 ± 9.6 64.1 ± 9.8 
Female sex, n (%) 944 (29.0) 1760 (33.8) 
Race, n (%)   
White 2024 (62.2) 2778 (53.3) 
Black 96 (3.0) 179 (3.4) 
Asian 861 (26.5) 1810 (34.7) 
Native American 3 (0.1) 6 (0.1 ) 
Pacific Islander 8 (0.2) 6 (0.1) 
Other 260 (8.0) 432 (8.3) 
Weight, kg 84.7 ± 19.5 81.8 ± 19.3 
Body mass index, kg/m2  30.3 ± 5.9 29.7 ± 5.9 
Duration of diabetes, n (%)   
< 1 years 106 (3.3) 180 (3.5) 
1-5 years 416 (12.8) 793 (15.2) 
>5 years 2730 (83.9) 4238 (81.3) 
Smoking history, n (%)   
Never 1539 (47.3) 2709 (52.0) 
Ex-smoker 1270 (39.1) 1825 (35.0) 
Current smoker 443 (13.6) 677 (13.0) 
Systolic blood pressure, mmHg 137.4 ± 16.1 137.2 ± 16.6 
Diastolic blood pressure, mmHg 74.2 ± 9.7 74.2 ± 9.9 
Glycated hemoglobin, % 7.7  ± 1.6 7.9  ± 1.7 
Glycated hemoglobin, mmol/mol 61±18 63±19 
Total cholesterol, mmol/l 4.4  ± 1.1 4.6  ± 1.2 
LDL cholesterol, mmol/l 2.5  ± 0.9 2.6  ± 1.0 
HDL cholesterol, mmol/l 1.2  ± 0.3 1.2  ± 0.3 
Triglycerides, mmol/l 1.8 [1.3, 2.6] 1.8 [1.2, 2.5] 
eGFR, ml/min/1.73m2 54.3 ± 21.3 57.7 ± 24.0 
Urinary albumin-to-creatinine ratio (geometric 
mean) 
26.9 [4.2,82.0] 36.3 [8.5,111.5] 
Medical history, n (%)   
Chronic heart failure 374 (11.5) 489 (9.4) 
Cardiovascular disease 1554 (47.1) 2065 (39.3) 
Unstable angina 364 (11.2) 441 (8.5) 
Percutaneous coronary intervention 500 (15.4) 707 (13.6) 
Coronary artery bypass surgery 493 (14.9) 564 (10.7) 
Hospitalization for myocardial infarction 585 (18.0) 828 (15.9) 
Hospitalization for stroke 359 (11.0) 477 (9.2) 
Transient ischemic attack 170 (5.2) 174 (3.3) 
Atrial fibrillation 289 (8.9) 435 (8.3) 
Amputation of toe/foot/leg 129 (4.0) 209 (4.0) 
Diabetic nephropathy  2070 (63.7) 3575 (68.6) 
Diabetic retinopathy  1170 (36.0) 1968 (37.8) 
Antihyperglycemic agents, n (%)   
Sulfonylurea 1156 (35.5) 1551 (29.8) 
Metformin 1553 (47.8) 2351 (45.1) 
Insulin 1748 (53.8) 3046 (58.5) 
Data are n (%), mean (SD), or median (IQR). HDL=high density lipoprotein, LDL=low density lipoprotein, 
 eGFR=estimated glomerular filtration rate 
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Table 2. Association of the questions and outcomes, unadjusted and adjusted models in patients who 
were randomized 2007-2008 (derivation group n=3252) 
 
 Unadjusted Adjusted* 
Question HR, 95 % CI p-value p-value  
(equality) 
HR, 95 % CI p-value p-value 
(equality) 
CV composite outcome 
 524 events 0.19 517 events  0.73 
Question 1 1.25 (1.04-1.50) 0.019  1.23 (1.02-1.49) 0.033  
Question 8 1.44 (1.18-1.76) <0.001  1.38 (1.13-1.70) 0.002  
Question 12 1.63 (1.36-1.95) <0.001  1.33 (1.09-1.61) 0.004  
Question 1- Are your legs and/or feet numb? Question 8-Have you ever had an open sore on your foot? Question 12- Do your 
legs hurt when you walk? *Model adjusted for age, sex, race, smoking status, systolic blood pressure, eGFR, urinary albumin to 
creatinine ratio, HF history, myocardial infarction, stroke, atrial fibrillation, diabetic nephropathy, diabetic retinopathy, 
amputation, claudication, unstable angina, coronary revascularization, duration of diabetes, HbA1c, and randomized treatment. 
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Table 3. Association of the questions and outcomes, Model 1 and 2 in patients who were randomized 
2009-2011 (validation group n=5211) 
 
 Model 1 Model 2 
Answer HR, 95 % CI p-value HR, 95 % CI p-value 
CV composite outcome 
 595 events 587 events 
Any “yes”  1.77 (1.48-2.11) <0.001 1.54 (1.28-1.85) <0.001 
All “yes”  2.08 (1.61-2.70) <0.001 1.70 (1.30-2.23) <0.001 
All-cause death 
 369 events 366 events 
Any “yes” 1.48 (1.19 -1.84) <0.001 1.23 (0.98-1.54) 0.072 
All “yes” 2.06 (1.51-2.81) <0.001 1.58 (1.14-2.19) 0.006 
CV death 
 222 events 220 events 
Any “yes”  1.51 (1.14-2.01) 0.004 1.24 (0.93-1.66) 0.15 
All “yes”  2.14 (1.44-3.18) <0.001 1.62 (1.06-2.46) 0.025 
Heart failure hospitalization 
 235 events 232 events 
Any “yes”  2.00 (1.50-2.68) <0.001 1.73 (1.28-2.33) <0.001 
All “yes”  2.20 (1.44-3.36) <0.001 1.75 (1.13-2.71)  0.013 
Myocardial infarction 
 145 events 143 events 
Any “yes”  2.20 (1.51-3.21) <0.001 1.86 (1.25-2.76) 0.002 
All “yes”  2.75 (1.63-4.65) <0.001 2.19 (1.26-3.80) 0.005 
Stroke 
 152 events 149 events 
Any “yes”  1.94 (1.36-2.78) <0.001 1.74 (1.19-2.53) 0.004 
All “yes” 1.70 (0.97-2.99) 0.066 1.42 (0.78-2.59) 0.25 
3 point MACE (CV death, non-fatal myocardial infarction, non-fatal stroke) 
 436 events 431 events 
Any “yes”  1.75 (1.42-2.15) <0.001 1.49 (1.51-1.85) <0.001 
All “yes” 2.10 (1.56-2.84) <0.001 1.69 (1.23-2.31) 0.001 
Model 1 adjusted for the randomized study treatment; Model 2 adjusted for age, sex, race, smoking status, systolic blood 
pressure, eGFR, urinary albumin to creatinine ratio, HF history, myocardial infarction, stroke, atrial fibrillation, diabetic 
nephropathy, diabetic retinopathy, amputation, claudication, unstable angina, coronary revascularization, duration of diabetes, 
HbA1c, and randomized treatment. Footnote to Table 3: For all reported hazard ratios above, no significant violations of the 
proportional hazards assumption were detected (p>0.05 for all) 
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Table 4. Harrell’s C statistics, continuous net reclassification improvement (NRI) and integrated 
discrimination improvement (IDI) 
 
Outcome With vs. without MNSI questions 
 Harrell’s C NRI IDI 
CV composite 
outcome 
C=0.70 vs 0.71, p= 0.010 +22%, (+10%, +31%), p=0.027 +0.9%, (+0.4%, +2.1%), p=0.007 
All-cause death C=0.71 vs 0.71, p= 0.12 +22%, (-3%, +36%), p=0.09 +0.5%, (+0.1%, +1.8%), p=0.020 
CV death C=0.72 vs 0.73, p= 0.15 +17%, (-5%, +31%), p=0.13 +0.3%, (0.0%, +1.6%), p=0.040 
Heart failure 
hospitalization 
C=0.78 vs 0.79, p= 0.003 +25%, (+11%, +33%), p<0.001 +0.4%, (-0.1%, +1.6%), p=0.11 
Myocardial 
infarction 
C=0.74 vs 0.75, p= 0.27 +24%, (+10%, +34%), p=0.013 +0.7%, (+0.2%, +2.8%), p<0.001 
Stroke C=0.70 vs 0.72, p= 0.045 +23%, (-13%, +48%), p=0.09 +0.4%, (-0.1%, +2.0%), p=0.07 
3 point MACE C=0.70 vs 0.72, p= 0.045 +22%, (+6%, +36%), p=0.033 +0.8%, (+0.3%, +2%), p=0.007 
CV-cardiovascular; 3 point MACE: CV death, non-fatal myocardial infarction, non-fatal stroke 
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Figure Legend 
 
 
Figure 1. The association of answer “yes” to any of the three questions (upper panel) and 
all three questions (lower panel) with adverse outcomes in patients who were randomized 
2009-2011 (validation group n=5211)  
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